{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T04:11:20Z","timestamp":1692591080810},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent insights into the pathogenesis of microvascular occlusion downstream of the sickled red cell have revealed new therapeutic targets for sickle cell disease (SCD). After the formation of sickle cells, tissue injury spurs inflammation, which leads to receptor-mediated contacts between sickle cells, leukocytes, and vascular endothelium. Specifically, selectins decelerate sickled red cells and leukocytes in the circulation to facilitate endothelial adhesion and other cell\u2013cell interactions, ultimately leading to vascular occlusion. Invariant NKT (iNKT) cells, activated during reperfusion, generate a broad inflammatory response, which further increases cellular adhesion and vascular occlusion. Novel therapies are in development that target selectins and iNKT cells to prevent or interrupt the vicious cycle of adhesion and inflammation. Although the therapies hold promise for the treatment of SCD, an underappreciated threat to their development is poor access to care for people with SCD. Unless the majority of people with SCD have access to consistent, high-quality care, they will not have the opportunity to participate in a clinical trial or receive any new therapy, regardless of its efficacy.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.426","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"426-432","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?"],"prefix":"10.1182","volume":"2015","author":[{"given":"Joshua J.","family":"Field","sequence":"first","affiliation":[{"name":"Medical Sciences Institute, Blood Center of Wisconsin; and"},{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111705511180400_B1","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2019111705511180400_B2","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/ATVBAHA.110.211615","article-title":"P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease","volume":"30","author":"Polanowska-Grabowska","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2019111705511180400_B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2009-02-205492","article-title":"NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines","volume":"114","author":"Wallace","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111705511180400_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice","volume":"116","author":"Chang","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111705511180400_B5","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2010-06-290643","article-title":"Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease","volume":"116","author":"Wallace","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111705511180400_B6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-148-12-200806170-00220","article-title":"National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease","volume":"148","author":"Brawley","year":"2008","journal-title":"Ann Intern Med"},{"issue":"9","key":"2019111705511180400_B7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2019111705511180400_B8","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2019111705511180400_B9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0092-8674(91)90393-D","article-title":"Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins","volume":"65","author":"Lawrence","year":"1991","journal-title":"Cell"},{"issue":"10","key":"2019111705511180400_B10","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2004-02-0713","article-title":"The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo","volume":"104","author":"Embury","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111705511180400_B11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2010-05-285718","article-title":"Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease","volume":"117","author":"Gutsaeva","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111705511180400_B12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nm.1939","article-title":"Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury","volume":"15","author":"Hidalgo","year":"2009","journal-title":"Nat Med"},{"issue":"4","key":"2019111705511180400_B13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10439-011-0507-y","article-title":"E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease","volume":"40","author":"Chase","year":"2012","journal-title":"Ann Biomed Eng"},{"issue":"6","key":"2019111705511180400_B14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/01.RES.79.6.1196","article-title":"Distinct phenotype of E-selectin-deficient mice: E-selectin is required for slow leukocyte rolling in vivo","volume":"79","author":"Kunkel","year":"1996","journal-title":"Circ Res"},{"issue":"3 Pt 2","key":"2019111705511180400_B15","first-page":"H1391","article-title":"TNF-alpha induces selectin-mediated leukocyte rolling in mouse cremaster muscle arterioles","volume":"272","author":"Kunkel","year":"1997","journal-title":"Am J Physiol"},{"issue":"22","key":"2019111705511180400_B16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood.V114.22.1526.1526","article-title":"Safety, tolerability and pharmacokinetics of GMI-1070, a pan-selectin inhibitor for treatment of vaso-occlusive crisis: single and multiple dose studies in healthy volunteers","volume":"114","author":"Xie","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111705511180400_B17","doi-asserted-by":"crossref","first-page":"e101301","DOI":"10.1371\/journal.pone.0101301","article-title":"Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia","volume":"9","author":"Wun","year":"2014","journal-title":"PLoS One"},{"issue":"17","key":"2019111705511180400_B18","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111705511180400_B19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood.V122.21.970.970","article-title":"Placebo-controlled, double-blind, first-in-human, single ascending dose and multiple dose, healthy subject study of intravenous-administered SelG1, a humanized anti-P-selectin antibody in development for sickle cell disease","volume":"122","author":"Stocker","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111705511180400_B20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00441-010-1023-3","article-title":"Invariant natural killer T cells: bridging innate and adaptive immunity","volume":"343","author":"Van Kaer","year":"2011","journal-title":"Cell Tissue Res"},{"issue":"51","key":"2019111705511180400_B21","doi-asserted-by":"crossref","first-page":"20490","DOI":"10.1073\/pnas.0710145104","article-title":"Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation","volume":"104","author":"Salio","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2019111705511180400_B22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri854","article-title":"The unconventional lifestyle of NKT cells","volume":"2","author":"Kronenberg","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2019111705511180400_B23","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1084\/jem.20061097","article-title":"Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation","volume":"203","author":"Lappas","year":"2006","journal-title":"J Exp Med"},{"issue":"21","key":"2019111705511180400_B24","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1182\/blood.V124.21.2697.2697","article-title":"Antibody mediated depletion of iNKT cells protects against hypoxia-induced pulmonary injury in a murine model of sickle cell disease","volume":"124","author":"Pei","year":"2014","journal-title":"Blood"},{"key":"2019111705511180400_B25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"2019111705511180400_B26","article-title":"Lexiscan [package insert]","author":"Astellas Pharma","year":"2009"},{"issue":"3","key":"2019111705511180400_B27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2019111705511180400_B28","doi-asserted-by":"crossref","first-page":"e74664","DOI":"10.1371\/journal.pone.0074664","article-title":"NF-kappaB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2019111705511180400_B29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hoc.2013.11.003","article-title":"The role of adenosine signaling in sickle cell therapeutics","volume":"28","author":"Field","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"17","key":"2019111705511180400_B30","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2012-11-465963","article-title":"Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson","volume":"121","author":"Field","year":"2013","journal-title":"Blood"},{"issue":"122","key":"2019111705511180400_B31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.V122.21.977.977","article-title":"A phase 1 single ascending dose study of NKTT120 in stable adult sickle cell patients","author":"Field","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111705511180400_B32","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood.V124.21.2718.2718","article-title":"NKTT120 reduces iNKT cells without dose limiting toxicities in stable adult sickle cell patients in a phase 1 trial","volume":"124","author":"Majerus","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111705511180400_B33","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bolanos-Meade","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111705511180400_B34","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"issue":"5858","key":"2019111705511180400_B35","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1152092","article-title":"Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin","volume":"318","author":"Hanna","year":"2007","journal-title":"Science"},{"issue":"6058","key":"2019111705511180400_B36","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.1211053","article-title":"Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing","volume":"334","author":"Xu","year":"2011","journal-title":"Science"},{"issue":"1","key":"2019111705511180400_B37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1748-0361.2000.tb00435.x","article-title":"Socioeconomic distress and health status: the urban-rural dichotomy of services utilization for people with sickle cell disorder in North Carolina","volume":"16","author":"Haque","year":"2000","journal-title":"J Rural Health"},{"issue":"1","key":"2019111705511180400_B38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0033-3549(04)50214-5","article-title":"Rural\/urban differences in access to and utilization of services among people in Alabama with sickle cell disease","volume":"118","author":"Telfair","year":"2003","journal-title":"Public Health Rep"},{"issue":"4","key":"2019111705511180400_B39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ajem.2012.11.005","article-title":"The impact of race and disease on sickle cell patient wait times in the emergency department","volume":"31","author":"Haywood","year":"2013","journal-title":"Am J Emerg Med"},{"issue":"17","key":"2019111705511180400_B40","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111705511180400_B41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776","article-title":"Clinical events in the first decade in a cohort of infants with sickle cell disease: Cooperative Study of Sickle Cell Disease","volume":"86","author":"Gill","year":"1995","journal-title":"Blood"},{"issue":"10","key":"2019111705511180400_B42","doi-asserted-by":"crossref","first-page":"E188","DOI":"10.1002\/ajh.23805","article-title":"Silent cerebral infarction, income, and grade retention among students with sickle cell anemia","volume":"89","author":"King","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111705511180400_B43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019111705511180400_B44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1037\/0278-6133.23.3.267","article-title":"Daily mood and stress predict pain, health care use, and work activity in African American adults with sickle-cell disease","volume":"23","author":"Gil","year":"2004","journal-title":"Health Psychol"},{"issue":"13","key":"2019111705511180400_B45","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.2010.378","article-title":"Acute care utilization and rehospitalizations for sickle cell disease","volume":"303","author":"Brousseau","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"2019111705511180400_B46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jpainsymman.2014.02.002","article-title":"Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease","volume":"48","author":"Haywood","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2019111705511180400_B47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/oxfordjournals.aje.a010288","article-title":"Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review","volume":"151","author":"Ashley-Koch","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2019111705511180400_B48","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1353\/hpu.2010.0940","article-title":"Problematic hospital experiences among adult patients with sickle cell disease","volume":"21","author":"Lattimer","year":"2010","journal-title":"J Health Care Poor Underserved"},{"issue":"3","key":"2019111705511180400_B49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.23912","article-title":"Intensive management of high-utilizing adults with sickle cell disease lowers admissions","volume":"90","author":"Koch","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/426\/1250791\/bep00115000426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/426\/1250791\/bep00115000426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T04:09:31Z","timestamp":1692504571000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/426\/20686\/Can-selectin-and-iNKT-cell-therapies-meet-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.426","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}